Prostate cancer screening guidelines and their alignment with recent literature

Area of Science:

• Oncology
• Urology
• Preventive Medicine

Background:

• Prostate-specific antigen (PSA) testing for prostate cancer screening is debated due to overscreening, overdiagnosis, and overtreatment.
• Current screening guidelines offer contradictory recommendations on initiation, frequency, and discontinuation.
• High-risk populations have specific, yet inconsistent, screening recommendations.

Purpose of the Study:

• To compare existing prostate cancer screening guidelines with recent research findings.
• To identify the guideline that most closely aligns with the latest scientific evidence.
• To evaluate the potential impact of different guidelines on screening outcomes.

Main Methods:

• Literature review comparing prostate cancer screening guidelines.
• Analysis of newer research relevant to PSA testing and prostate cancer detection.
• Comparative assessment of guideline recommendations against current evidence.

Main Results:

• The American Urological Association and National Comprehensive Cancer Network guidelines may result in over- or under-screening.
• The American Cancer Society (ACS) guideline demonstrates the strongest alignment with recent research.
• Following the ACS guideline may capture most clinically significant prostate cancers while minimizing overscreening and overdiagnosis.

Conclusions:

• The ACS guideline offers a more evidence-based approach to prostate cancer screening.
• Adopting the ACS guideline could improve the balance between detecting significant prostate cancer and avoiding unnecessary interventions.
• Further evaluation of guideline adherence and patient outcomes is warranted.